Skip to main content
Erschienen in: Journal of Thrombosis and Thrombolysis 1/2017

09.05.2017

Perioperative bleeding and thrombotic risks in patients with Von Willebrand disease

verfasst von: Nathaniel R. Smilowitz, Navdeep Gupta, Yu Guo, Sripal Bangalore, Jeffrey S. Berger

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Von Willebrand disease (VWD) is an inherited bleeding disorder that often manifests clinically with hemorrhage after invasive procedures. We investigated the association between a diagnosis of VWD and bleeding and thrombotic outcomes following major non-cardiac surgery in a large national database from the United States. Patients age ≥45 years requiring major non-cardiac surgery were identified from Healthcare Cost and Utilization Project’s National Inpatient Sample data. Von Willebrand disease, perioperative major adverse cardiovascular events (MACE), thrombotic events, and hemorrhage were defined by ICD9 diagnosis codes. From 2004 to 2013, a total of 10,581,621 hospitalizations for major non-cardiac surgery met study inclusion criteria and VWD was identified in 3765 (0.036%). In adjusted analyses, patients with VWD were significantly more likely to develop post-operative hemorrhage than patients without VWD (5.5 vs. 1.9%, p < 0.001; adjusted OR 3.49, 95% CI 3.03–4.03), but had similar odds of perioperative MACE and thrombotic events. Thus, a diagnosis of VWD was associated with increased risks of bleeding with non-cardiac surgery, without a corresponding reduction in perioperative thrombosis in comparison to patients without VWD. Perioperative management of patients with hereditary bleeding disorders and mitigation of thrombotic risks requires further study.
Literatur
1.
Zurück zum Zitat Sadler JE, Mannucci PM, Berntorp E, Bochkov N, Boulyjenkov V, Ginsburg D, Meyer D, Peake I, Rodeghiero F, Srivastava A (2000) Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost 84(2):160–174PubMed Sadler JE, Mannucci PM, Berntorp E, Bochkov N, Boulyjenkov V, Ginsburg D, Meyer D, Peake I, Rodeghiero F, Srivastava A (2000) Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost 84(2):160–174PubMed
2.
Zurück zum Zitat Mannucci PM, Chediak J, Hanna W, Byrnes J, Ledford M, Ewenstein BM, Retzios AD, Kapelan BA, Schwartz RS, Kessler C, Alphanate Study G (2002) Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study. Blood 99(2):450–456CrossRefPubMed Mannucci PM, Chediak J, Hanna W, Byrnes J, Ledford M, Ewenstein BM, Retzios AD, Kapelan BA, Schwartz RS, Kessler C, Alphanate Study G (2002) Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study. Blood 99(2):450–456CrossRefPubMed
3.
Zurück zum Zitat Chapin J, Bamme J, Hsu F, Christos P, DeSancho M (2017) Outcomes in patients with hemophilia and von Willebrand disease undergoing invasive or surgical procedures. Clin Appl Thromb Hemost 23(2):148–154CrossRefPubMed Chapin J, Bamme J, Hsu F, Christos P, DeSancho M (2017) Outcomes in patients with hemophilia and von Willebrand disease undergoing invasive or surgical procedures. Clin Appl Thromb Hemost 23(2):148–154CrossRefPubMed
4.
Zurück zum Zitat Seaman CD, Yabes J, Comer DM, Ragni MV (2015) Does deficiency of von Willebrand factor protect against cardiovascular disease? Analysis of a national discharge register. J Thromb Haemost 13(11):1999–2003CrossRefPubMed Seaman CD, Yabes J, Comer DM, Ragni MV (2015) Does deficiency of von Willebrand factor protect against cardiovascular disease? Analysis of a national discharge register. J Thromb Haemost 13(11):1999–2003CrossRefPubMed
5.
Zurück zum Zitat Sanders YV, Eikenboom J, de Wee EM, van der Bom JG, Cnossen MH, Degenaar-Dujardin ME, Fijnvandraat K, Kamphuisen PW, Laros-van Gorkom BA, Meijer K, Mauser-Bunschoten EP, Leebeek FW, Wi NSG (2013) Reduced prevalence of arterial thrombosis in von Willebrand disease. J Thromb Haemost 11(5):845–854CrossRefPubMed Sanders YV, Eikenboom J, de Wee EM, van der Bom JG, Cnossen MH, Degenaar-Dujardin ME, Fijnvandraat K, Kamphuisen PW, Laros-van Gorkom BA, Meijer K, Mauser-Bunschoten EP, Leebeek FW, Wi NSG (2013) Reduced prevalence of arterial thrombosis in von Willebrand disease. J Thromb Haemost 11(5):845–854CrossRefPubMed
6.
Zurück zum Zitat Smilowitz NR, Gupta N, Ramakrishna H, Guo Y, Berger JS, Bangalore S (2017) Perioperative major adverse cardiovascular and cerebrovascular events associated with noncardiac surgery. JAMA Cardiol 2(2):181–187CrossRefPubMed Smilowitz NR, Gupta N, Ramakrishna H, Guo Y, Berger JS, Bangalore S (2017) Perioperative major adverse cardiovascular and cerebrovascular events associated with noncardiac surgery. JAMA Cardiol 2(2):181–187CrossRefPubMed
7.
Zurück zum Zitat Siboni SM, Biguzzi E, Solimeno LP, Pasta G, Mistretta C, Mannucci PM, Peyvandi F (2014) Orthopaedic surgery in patients with von Willebrand disease. Haemophilia 20(1):133–140CrossRefPubMed Siboni SM, Biguzzi E, Solimeno LP, Pasta G, Mistretta C, Mannucci PM, Peyvandi F (2014) Orthopaedic surgery in patients with von Willebrand disease. Haemophilia 20(1):133–140CrossRefPubMed
8.
Zurück zum Zitat Zulfikar B, Koc B, Ak G, Dikici F, Karaman I, Atalar AC, Bezgal F (2016) Surgery in patients with von Willebrand disease. Blood Coagul Fibrinolysis 27(7):812–816CrossRefPubMed Zulfikar B, Koc B, Ak G, Dikici F, Karaman I, Atalar AC, Bezgal F (2016) Surgery in patients with von Willebrand disease. Blood Coagul Fibrinolysis 27(7):812–816CrossRefPubMed
9.
Zurück zum Zitat Miesbach W, Berntorp E (2017) Von Willebrand disease: the ‘Dos’ and ‘Don’ts’ in surgery. Eur J Haematol 98(2):121–127CrossRefPubMed Miesbach W, Berntorp E (2017) Von Willebrand disease: the ‘Dos’ and ‘Don’ts’ in surgery. Eur J Haematol 98(2):121–127CrossRefPubMed
Metadaten
Titel
Perioperative bleeding and thrombotic risks in patients with Von Willebrand disease
verfasst von
Nathaniel R. Smilowitz
Navdeep Gupta
Yu Guo
Sripal Bangalore
Jeffrey S. Berger
Publikationsdatum
09.05.2017
Verlag
Springer US
Erschienen in
Journal of Thrombosis and Thrombolysis / Ausgabe 1/2017
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-017-1504-2

Weitere Artikel der Ausgabe 1/2017

Journal of Thrombosis and Thrombolysis 1/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.